Longitudinal Changes in Albuminuria and Estimated Glomerular Filtration Rate in Patients with Type 2 Diabetes Treated with Empagliflozin or Canagliflozin: A Real-World Cohort Study
Longitudinale Veränderungen von Albuminurie und geschätzter glomerulärer Filtrationsrate bei Patient:innen mit Typ-2-Diabetes unter Empagliflozin oder Canagliflozin: Real-World-Kohortenstudie
Journal of Clinical Medicine · 05.11.2026 · 15 (21) · 8631
DOI: 10.3390/jcm15218631 ↗Auf einen Blick
Bei 215 Erwachsenen mit Typ-2-Diabetes waren die Verläufe von eGFR und UACR unter Empagliflozin und Canagliflozin über 18 Monate vergleichbar. Ein Unterschied bei der UACR-Reduktion zeigte sich nur vorübergehend nach 12 Monaten.
Fragestellung
Unterscheiden sich Empagliflozin und Canagliflozin bei Patient:innen mit Typ-2-Diabetes in den longitudinalen Veränderungen von eGFR und UACR?
Methode
Retrospektive Beobachtungskohortenstudie an einem tertiären Zentrum; 215 Erwachsene mit Typ-2-Diabetes erhielten Empagliflozin oder Canagliflozin. Verlauf von eGFR und UACR über 18 Monate; multivariable und lineare Mixed-Effects-Modelle.
Ergebnisse
18-Monats-Änderung der eGFR: kein signifikanter Unterschied zwischen Canagliflozin und Empagliflozin (adjustierte β −0,43 mL/min/1,73 m2; 95 %-KI −4,12 bis 3,26; p = 0,819). Kein signifikanter Behandlungs-Zeit-Interaktionseffekt für eGFR oder UACR.
Schlussfolgerung der Autor:innen
Empagliflozin und Canagliflozin zeigten über 18 Monate vergleichbare eGFR- und UACR-Verläufe. Die größere Wahrscheinlichkeit für eine ≥30 % UACR-Reduktion nach 12 Monaten war nicht bis 18 Monate anhaltend.
Kernaussagen
- eGFR-Verlauf über 18 Monate zwischen den Gruppen vergleichbar
- UACR-Reduktion ≥30 % nach 12 Monaten unter Canagliflozin seltener
- Kein Hinweis auf Überlegenheit eines SGLT2-Inhibitors bei renalen Outcomes
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 05.11.2026. Verfasst von Ching-Yao Cheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Taichung Veterans General Hospital, Taichung City 407, Taiwan. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taichung Veterans General Hospital, Taiwan.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Direct real-world comparisons of empagliflozin and canagliflozin regarding renal outcomes in patients with type 2 diabetes mellitus (T2DM) remain limited. This study compared longitudinal changes in the estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR).
Methods
This retrospective observational cohort study included 215 adults with type 2 diabetes mellitus who received either empagliflozin (n = 115) or canagliflozin (n = 100) at a tertiary medical center. Renal outcomes, including estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR), were evaluated over 18 months. Between-group differences in renal outcomes were assessed using multivariable regression models adjusted for relevant baseline clinical characteristics. Linear mixed-effects models were additionally employed to account for repeated measurements and evaluate differences in longitudinal trajectories between treatment groups. A reduction in UACR of ≥30% from baseline was evaluated as a clinically meaningful albuminuria response using multivariable logistic regression. Subgroup analyses were performed according to age and baseline UACR.
Results
In multivariable linear regression analysis, the 18-month change in eGFR did not differ significantly between canagliflozin and empagliflozin (adjusted β, −0.43 mL/min/1.73 m2; 95% confidence interval [CI], −4.12 to 3.26; p = 0.819). Consistently, linear mixed-effects models showed no significant treatment-by-time interaction for eGFR (p for interaction = 0.356) or log-transformed UACR (p for interaction = 0.104). In the adjusted logistic regression analysis, canagliflozin was associated with lower odds of achieving a ≥30% reduction in UACR at 12 months compared with empagliflozin (adjusted odds ratio [OR], 0.40; 95% CI, 0.20–0.79; p = 0.008). However, this association was not statistically significant at 18 months (adjusted OR, 0.62; 95% CI, 0.32–1.18; p = 0.147). Subgroup interaction analyses did not demonstrate significant effect modification by age or baseline UACR (p for interaction = 0.859 and 0.626, respectively).
Conclusions
In this real-world cohort of patients with type 2 diabetes mellitus, empagliflozin and canagliflozin showed comparable longitudinal eGFR and UACR trajectories over 18 months. Although a difference in the likelihood of achieving a ≥30% reduction in UACR was observed at 12 months, this finding was not sustained at 18 months and should be interpreted cautiously. Overall, our findings do not establish the superiority of either SGLT2 inhibitor in terms of renal outcomes. Further studies with larger populations and prospective designs are warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Taichung Veterans General Hospital, Taichung City 407, Taiwan.
- School of Pharmacy, China Medical University, Taichung City 404, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung City 407, Taiwan.
- Department of Life Science, Tunghai University, Taichung City 407, Taiwan.
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung City 402, Taiwan.
- Division of Clinical Informatics, Department of Digital Medicine, Taichung Veterans General Hospital, 160, Sec. 3, Taiwan Boulevard, Taichung City 407, Taiwan.
ORCID-Profile: Ching-Yao Cheng, Jaw-Horng Liou, Shang-Feng Tsai
Förderung
- Taichung Veterans General Hospital, Taiwan
Zitieren
APA
Cheng, C. Y., Liou, J. H., Wei, K. T., & Tsai, S. F. (2026). Longitudinal Changes in Albuminuria and Estimated Glomerular Filtration Rate in Patients with Type 2 Diabetes Treated with Empagliflozin or Canagliflozin: A Real-World Cohort Study. Journal of Clinical Medicine, 15(21), 8631. https://doi.org/10.3390/jcm15218631
Vancouver
Cheng CY, Liou JH, Wei KT, Tsai SF. Longitudinal Changes in Albuminuria and Estimated Glomerular Filtration Rate in Patients with Type 2 Diabetes Treated with Empagliflozin or Canagliflozin: A Real-World Cohort Study. Journal of Clinical Medicine. 2026;15(21):8631. doi:10.3390/jcm15218631
BibTeX
@article{Cheng2026,
author = {Cheng, Ching-Yao and Liou, Jaw-Horng and Wei, Kao Tz and Tsai, Shang-Feng},
title = {Longitudinal Changes in Albuminuria and Estimated Glomerular Filtration Rate in Patients with Type 2 Diabetes Treated with Empagliflozin or Canagliflozin: A Real-World Cohort Study},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {21},
pages = {8631},
doi = {10.3390/jcm15218631}
}
EUVIMED